SCHEMBL7002379

SCHEMBL7002379

[O-][n+]1ccc2ccc(Br)cc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.46
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
ACHE P22303 1/20 0.35
BACE1 P56817 2/20 0.34
ERN1 O75460 1/20 0.33
GPR84 Q9NQS5 1/20 0.33
NCEH1 Q6PIU2 1/20 0.33
AHR P35869 3/20 0.32
NR4A2 P43354 1/20 0.32
LMNA P02545 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PIM1 P11309 1/20 0.31
NOS1 P29475 2/20 0.31
METAP2 P50579 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31426083 1.00 CYP2A6 (0.46) CYP2A6KDM4EMEN1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL6435395 0.98 CYP2A6 (0.45) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL1536308 0.92 CYP2A6 (0.46) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL31556379 0.92 CYP2A6 (0.46) CYP2A6KDM4EMEN1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL6435272 0.90 CYP2A6 (0.45) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL23088139 0.75 CYP2A6 (0.46) CYP2A6MAPTGPR84AHRNR4A2
SCHEMBL18733501 0.75 CYP1A2 (0.46) CYP2A6ACHEBACE1AHRCYP1A2
SCHEMBL29792856 0.75 CYP2A6 (0.46) CYP2A6MAPTGPR84AHRNR4A2
SCHEMBL25252937 0.75 CYP1A2 (0.52) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL22093950 0.72 CYP2A6 (0.55) CYP2A6KDM4EMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2025-03-13 US disclosed
EP-4463444-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS Merck Patent GmbH (DE) 2024-11-20 EP disclosed
WO-2023131690-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2023-07-13 WO disclosed
CN-109206457-A Red phosphorescent compound and the organic electroluminescence device for using the compound 宇瑞(上海)化学有限公司 2019-01-15 CN disclosed
EP-1023268-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER LTD (GB) 2003-05-21 EP disclosed
US-6248738-B1 ANTIULCER AGENTS, ANGIOGENESIS INHIBITORS, ANTIMETASTASIS AGENTS, ANTITUMOR AGENTS PFIZER INC. 2001-06-19 US disclosed
CN-1275979-A Isoquinoline compounds useful as urokinase inhibitors PFIZER (US) 2000-12-06 CN disclosed
EP-1023268-A1 ISOQUINOLINES AS UROKINASE INHIBITORS Pfizer Limited (GB) 2000-08-02 EP disclosed
WO-1999020608-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER LIMITED (GB) 1999-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS VHL, CDKN1A, CCNI CYP2A6 3732/4885KDM4E 1053/4885MEN1 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.